ACS Fall 2026: What To Expect?
In the 2025 edition of ACS Fall in Washington, DC, we saw the first disclosures of 13 clinical candidates spanning oncology, sickle cell disease, inflammatory bowel disease, heart failure, and Parkinson's disease imaging. As we look forward to this year's edition of ACS Fall in Chicago, we can take a look at the current line-up of speakers and first disclosures to give us an idea of what to expect later this week: @[Hong Lin](urn:li:person:dBqK46SyX\_), @[Quanta Therapeutics](urn:li:organization:74769054): QTX3034, a KRASG12D-preferring multi-KRAS allosteric inhibitor for KRASG12D-driven cancers @[Gerjan de Bruin](urn:li:person:UzsrfQshcr), @[Acerta Pharma B.V. \(A member of the AstraZeneca Group\)](urn:li:organization:4000527): AZD3632, a potential best-in-class Menin inhibitor @[Simone Bonazzi](urn:li:person:6s60LC8EW8), @[Novartis](urn:li:organization:1406): KFA115, a first-in-class selective IKZF2/IKZF4 molecular glue degrader for immuno-oncology @[Jiashi Wang](urn:li:person:AwKj-X537B), @[Schrödinger](urn:li:organization:35342) SGR-3515, a first-in-class Wee1/Myt1 inhibitor for advanced solid tumours Tao Jiang, @[GenFleet Therapeutics](urn:li:organization:72013348): GFH647, a next generation non-covalent BTK inhibitor for resistant B-cell malignancies @[Ramsay Beveridge](urn:li:person:z8QaICM7hz), @[Ventus Therapeutics](urn:li:organization:55040993): VENT-03, a potential first-in-class cGAS inhibitor, currently in Phase 2 for SLE @[Gwenaella \(Gwen\) Rescourio](urn:li:person:-KWFYj3GzT), @[Pfizer](urn:li:organization:1185): a clinical topical acetyl CoA carboxylase \(ACC\) inhibitor for acne vulgaris @[Craig E. Stivala](urn:li:person:HfKyylHM-u), @[Deep Apple Therapeutics](urn:li:organization:81306281): DAT-003, a potent and selective small molecule antagonist of MRGPRX2 Guangyan Du, @[Blueprint Medicines](urn:li:organization:2237668): BLU-808, a potent and selective oral wild-type KIT inhibitor for mast cell-driven diseases @[Laurel Mydock-McGrane](urn:li:person:l2OtXGnQDm), @[Fimbrion Therapeutics, Inc.](urn:li:organization:28641788): GSK3882347, an orally bioavailable FimH antagonist for uncomplicated urinary tract infections @[Sarah Bronner](urn:li:person:KnVYXP-EK2), @[Maze Therapeutics](urn:li:organization:19046855): MZE829, a small molecule inhibitor of APOL1 for APOL1-mediated chronic kidney disease Nathan Fuller, @[Rectify Pharma](urn:li:organization:76488484): RTY-406, a positive functional modulator of ABCB4 and BSEP for primary sclerosing cholangitis @[Kevin Filipski](urn:li:person:JcPpfT41ls), @[Pfizer](urn:li:organization:1185): PF-07976016, a small molecule GIPR antagonist for obesity Thank you to the @[ACS Division of Medicinal Chemistry](urn:li:organization:11777812) organising committee and the speakers for what promises to be an insightful event later this week. Like all the medchem community we are excited to hear these fantastic talks and look forward to two fantastic sessions. Which talk excites you most in the 2026 line up?